We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

16 hedge funds and large institutions have $429K invested in Galmed Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

45% more funds holding

Funds holding: 11 → 16 (+5)

2% more capital invested

Capital invested by funds: $419K → $429K (+$10.1K)

0.8% more ownership

Funds ownership: 0.71% → 1.51% (+0.8%)

Holders
16
Holders Change
+5
Holders Change %
+45.45%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
2
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
+$276K
2
CH
CVI Holdings
Delaware
+$276K
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$56K
4
Citadel Advisors
Citadel Advisors
Florida
+$44.7K
5
Two Sigma Investments
Two Sigma Investments
New York
+$34K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$261K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$74.5K
3
TRCT
Tower Research Capital (TRC)
New York
-$152
Name Holding Trade Value Shares
Change 		Change in
Stake
Walleye Capital
1
Walleye Capital
New York
$155K +$276K +20,814 New
CH
2
CVI Holdings
Delaware
$155K +$276K +20,782 New
Two Sigma Advisers
3
Two Sigma Advisers
New York
$31.4K +$56K +4,219 New
Citadel Advisors
4
Citadel Advisors
Florida
$25.1K +$44.7K +3,372 New
Two Sigma Investments
5
Two Sigma Investments
New York
$19K +$34K +2,560 New
VF
6
Virtu Financial
New York
$18K +$32.7K +2,467 New
Millennium Management
7
Millennium Management
New York
$12.5K +$5.78K +436 +35%
Morgan Stanley
8
Morgan Stanley
New York
$12.4K +$8.31K +627 +60%
TFGT
9
TS Financial Group (TSFG)
Illinois
$1K – – –
Wells Fargo
10
Wells Fargo
California
$126 – – –
FDCDDQ
11
Federation des caisses Desjardins du Quebec
Quebec, Canada
$104 – – –
Osaic Holdings
12
Osaic Holdings
Arizona
$32 +$53 +4 New
BCM
13
Bourgeon Capital Management
Connecticut
$22 – – –
UBS Group
14
UBS Group
Switzerland
$17 +$27 +2 New
AF
15
Allworth Financial
California
$11 – – –
EWP
16
Elevation Wealth Partners
California
$5 – – –
Bank of America
17
Bank of America
North Carolina
$1 – – –
BI
18
BVF Inc
California
– -$261K -7,488 Closed
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
– -$74.5K -2,133 Closed
TRCT
20
Tower Research Capital (TRC)
New York
– -$152 -4 Closed

GLMD Hedge Fund Activity: Q3 2023 in Review

16 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2023, worth a combined $429K — up 2.4% from $419K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new GLMD positions and 3 closed out — a net gain of 5 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Walleye Capital, opening a new position worth an estimated $276K. The largest seller was BVF Inc, exiting entirely with an estimated $261K sold.

  • 16 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2023, up from 11 in Q2 2023.
  • Funds reported $429K of Galmed Pharmaceuticals stock for Q3 2023, up 2.4% quarter-over-quarter.
  • 8 funds opened new Galmed Pharmaceuticals positions in Q3 2023 and 3 closed out, a net change of +5 holders.
  • The largest Galmed Pharmaceuticals buyer in Q3 2023 was Walleye Capital, an estimated $276K added.
  • The largest Galmed Pharmaceuticals seller in Q3 2023 was BVF Inc, an estimated $261K sold.

Based on aggregated 13F filings for Q3 2023.